Arrowhead price target raised to $24.50 from $17.50 at Chardan
Chardan analyst Keay Nake raised Buy rated Arrowhead’s price target to $24.50 from $17.50 to reflect increased confidence in the probability of success for the hepatitis B virus franchise.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.